This is an initiative by Cancer Research and Statistic Foundation, Supported by AstraZeneca, Pfizer & Roche and  lab partner 4baseCare

LuNGS Alliance, an initiative led by the Cancer Research and Statistic Foundation (CRSF), has announced free Lung NGS (Next Generation Sequencing) biomarker testing for lung cancer patients across India. This initiative is backed by leading pharmaceutical companies AstraZeneca, Pfizer, and Roche, with 4baseCare serving as the official lab partner.

The TARGT First Solid test by 4baseCare offers a comprehensive analysis of 72 commonly mutated genes, identifying actionable biomarkers that enable personalised treatment plans based on a patient’s unique genomic profile. This cutting-edge test identifies mutations corresponding to approved therapies by the FDA and NCCN (National Comprehensive Cancer Network), empowering oncologists to provide tailored, more effective treatments that can significantly improve patient outcomes. The primary goal of this initiative is to bridge the gap between innovative cancer care and its accessibility. By offering zero-cost biomarker testing, LuNGS Alliance ensures that financial constraints do not prevent patients from receiving the most advanced cancer treatment available.

Dr Kumar Prabhash from Cancer Research and Statistic Foundation said, “We are committed to ensuring lung cancer patients in India have access to effective, targeted treatments. With precision oncology, we aim to make life-saving innovations accessible and transform cancer care nationwide.”

Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, “Advanced NGS-based biomarker testing should be standard for every lung cancer patient. This initiative brings us closer to democratising precision medicine and making a real difference in patients’ lives."